IMAX Expands Partnership with Georgia Theatre Company for Five New Laser Locations

What happened

IMAX announced an agreement with Georgia Theatre Company to install five new IMAX with Laser systems in the southeastern U.S., expanding an existing partnership. The deal adds to IMAX's 478-system backlog, though it represents a modest incremental gain relative to the overall network of ~1,800 screens. The expansion supports the narrative of steady system signings, but the company's TAM remains capped at ~3,619 multiplex locations with ~48% already penetrated. Despite positive news, the DeepValue report assigns a POTENTIAL SELL rating, emphasizing that current valuations at ~48x trailing EPS already price in record 2025 performance and a flawless 2026 slate. The new locations provide incremental recurring revenue but do little to alter the risk-reward skew given high expectations and cyclical dependencies.

Implication

The five new locations add to IMAX's backlog but represent less than 1% of its installed base, doing little to move the needle on near-term financials. Investors should view this as routine business development rather than a catalyst that changes the fundamental outlook. The DeepValue analysis highlights that the stock's ~48x P/E already reflects perfection, leaving no room for error if the 2026 slate underperforms or China stumbles. The expansion supports network growth but does not address the structural concerns about TAM saturation and cyclical volatility. For disciplined investors, the prudent move is to wait for a larger margin of safety or clearer evidence that the high box-office trajectory is sustainable.

Thesis delta

The news reinforces IMAX's ability to sign new deals but does not alter the core thesis that the stock is fully priced for a best-case scenario. The thesis remains cautious: at $35, the risk-reward is unfavorable given limited upside to a ~$45 bull case and credible downside to the mid-$20s. This expansion, while positive, does not change the elevated expectations embedded in the valuation.